BioCentury
ARTICLE | Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

January 12, 2021 12:37 AM UTC

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only gained support during the pandemic.

The series B round, which comes one year after the company’s launch at last year’s J.P. Morgan Healthcare conference, includes participation from all of its series A investors plus additional life science specialists, mutual and private equity funds, sovereign wealth and family offices, payers and health systems. It brings the company’s total funding to about $750 million...

BCIQ Company Profiles

EQRx Inc.